Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis

Identifieur interne : 002683 ( PascalFrancis/Corpus ); précédent : 002682; suivant : 002684

Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis

Auteurs : Marcelo Merello ; Maria I. Nouzeilles ; Gabriel Piran Arce ; Ramon Leiguarda

Source :

RBID : Pascal:02-0456874

Descripteurs français

English descriptors

Abstract

Clinical idiopathic Parkinson's disease (PD) diagnosis requires following strict clinical criteria. Final definitive diagnosis can only be made after pathological confirmation and, despite following clinical criteria, several cases are mis-diagnosed. We assessed sensitivity and specificity of acute challenge with levodopa (L-dopa) to predict sustained long-term L-dopa responsiveness as a major criterion for clinical diagnosis of PD. A consecutive series of 82 patients first seen at a movement disorders clinic with a parkinsonian syndrome without specific diagnosis was included. A second examiner, blind to the presumptive diagnosis, performed in each patient an acute challenge with 250/50 mg of L-dopa-carbidopa and rated the test as positive or negative according to whether values reached a minimal 30% of improvement on UPDRS scores. Positive tests were considered supportive of presumptive clinical diagnosis of Parkinson's disease. Blind to test results and according to clinical presumption, the first examiner started patient treatment with the necessary L-dopa dose or, alternatively, until reaching 1 g for 1 month in those who failed to display a positive test response. At 24 month follow-up, they were re-tested with 1 g for 1 month when required. At this point, clinical criteria of the U.K. Parkinson's Disease Society Brain Bank were applied and definitive clinical diagnosis of PD was made. Sensitivity, specificity, and positive predictive ratio for acute challenge were calculated. Overall sensitivity and specificity of acute L-dopa challenge to predict clinical diagnosis of PD was 70.9% and 81.4%, respectively; positive predictive ratio was 88.6%. When patients were divided into three groups according to their UPDRS motor section score at initial examination, sensitivity and specificity varied: Group I (≤ 10), 71.4% and 100%; Group II (11-20), 75% and 75%; and Group III (≥21), 36.4% and 87%, respectively. Positive predictive ratio increased to 100% in Group I and to 87.5% in Group III. The positive result of initial acute L-dopa challenge predicts chronic L-dopa responsiveness as major criterion of PD in all patients with UPDRS motor scores lower than 10.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

pA  
A01 01  1    @0 0885-3185
A03   1    @0 Mov. disord.
A05       @2 17
A06       @2 4
A08 01  1  ENG  @1 Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis
A11 01  1    @1 MERELLO (Marcelo)
A11 02  1    @1 NOUZEILLES (Maria I.)
A11 03  1    @1 PIRAN ARCE (Gabriel)
A11 04  1    @1 LEIGUARDA (Ramon)
A14 01      @1 Movement Disorders Section, Raul Carrea Institute for Neurological Research (FLENI) @2 Buenos Aires @3 ARG @Z 1 aut. @Z 2 aut. @Z 3 aut.
A14 02      @1 Department of Neurology, Raul Carrea Institute for Neurological Research (FLENI) @2 Buenos Aires @3 ARG @Z 1 aut. @Z 4 aut.
A20       @1 795-798
A21       @1 2002
A23 01      @0 ENG
A43 01      @1 INIST @2 20953 @5 354000108922560290
A44       @0 0000 @1 © 2002 INIST-CNRS. All rights reserved.
A45       @0 23 ref.
A47 01  1    @0 02-0456874
A60       @1 P @3 CC
A61       @0 A
A64 01  1    @0 Movement disorders
A66 01      @0 USA
C01 01    ENG  @0 Clinical idiopathic Parkinson's disease (PD) diagnosis requires following strict clinical criteria. Final definitive diagnosis can only be made after pathological confirmation and, despite following clinical criteria, several cases are mis-diagnosed. We assessed sensitivity and specificity of acute challenge with levodopa (L-dopa) to predict sustained long-term L-dopa responsiveness as a major criterion for clinical diagnosis of PD. A consecutive series of 82 patients first seen at a movement disorders clinic with a parkinsonian syndrome without specific diagnosis was included. A second examiner, blind to the presumptive diagnosis, performed in each patient an acute challenge with 250/50 mg of L-dopa-carbidopa and rated the test as positive or negative according to whether values reached a minimal 30% of improvement on UPDRS scores. Positive tests were considered supportive of presumptive clinical diagnosis of Parkinson's disease. Blind to test results and according to clinical presumption, the first examiner started patient treatment with the necessary L-dopa dose or, alternatively, until reaching 1 g for 1 month in those who failed to display a positive test response. At 24 month follow-up, they were re-tested with 1 g for 1 month when required. At this point, clinical criteria of the U.K. Parkinson's Disease Society Brain Bank were applied and definitive clinical diagnosis of PD was made. Sensitivity, specificity, and positive predictive ratio for acute challenge were calculated. Overall sensitivity and specificity of acute L-dopa challenge to predict clinical diagnosis of PD was 70.9% and 81.4%, respectively; positive predictive ratio was 88.6%. When patients were divided into three groups according to their UPDRS motor section score at initial examination, sensitivity and specificity varied: Group I (≤ 10), 71.4% and 100%; Group II (11-20), 75% and 75%; and Group III (≥21), 36.4% and 87%, respectively. Positive predictive ratio increased to 100% in Group I and to 87.5% in Group III. The positive result of initial acute L-dopa challenge predicts chronic L-dopa responsiveness as major criterion of PD in all patients with UPDRS motor scores lower than 10.
C02 01  X    @0 002B17G
C02 02  X    @0 235
C03 01  X  FRE  @0 Parkinson maladie @5 01
C03 01  X  ENG  @0 Parkinson disease @5 01
C03 01  X  SPA  @0 Parkinson enfermedad @5 01
C03 02  X  FRE  @0 Idiopathique @5 02
C03 02  X  ENG  @0 Idiopathic @5 02
C03 02  X  SPA  @0 Idiopático @5 02
C03 03  X  FRE  @0 Epreuve pharmacologique @5 04
C03 03  X  ENG  @0 Pharmacologic test @5 04
C03 03  X  SPA  @0 Prueba farmacológica @5 04
C03 04  X  FRE  @0 Lévodopa @2 NK @2 FR @5 05
C03 04  X  ENG  @0 Levodopa @2 NK @2 FR @5 05
C03 04  X  SPA  @0 Levodopa @2 NK @2 FR @5 05
C03 05  X  FRE  @0 Antiparkinsonien @5 06
C03 05  X  ENG  @0 Antiparkinson agent @5 06
C03 05  X  SPA  @0 Antiparkinsoniano @5 06
C03 06  X  FRE  @0 Long terme @5 07
C03 06  X  ENG  @0 Long term @5 07
C03 06  X  SPA  @0 Largo plazo @5 07
C03 07  X  FRE  @0 Chimiothérapie @5 08
C03 07  X  ENG  @0 Chemotherapy @5 08
C03 07  X  SPA  @0 Quimioterapia @5 08
C03 08  X  FRE  @0 Sensibilité @5 10
C03 08  X  ENG  @0 Sensitivity @5 10
C03 08  X  SPA  @0 Sensibilidad @5 10
C03 09  X  FRE  @0 Spécificité @5 11
C03 09  X  ENG  @0 Specificity @5 11
C03 09  X  SPA  @0 Especificidad @5 11
C03 10  X  FRE  @0 Valeur prédictive @5 12
C03 10  X  ENG  @0 Predictive value @5 12
C03 10  X  SPA  @0 Valor predictivo @5 12
C03 11  X  FRE  @0 Evolution @5 16
C03 11  X  ENG  @0 Evolution @5 16
C03 11  X  SPA  @0 Evolución @5 16
C03 12  X  FRE  @0 Diagnostic @5 17
C03 12  X  ENG  @0 Diagnosis @5 17
C03 12  X  SPA  @0 Diagnóstico @5 17
C03 13  X  FRE  @0 Traitement @5 18
C03 13  X  ENG  @0 Treatment @5 18
C03 13  X  SPA  @0 Tratamiento @5 18
C03 14  X  FRE  @0 Pronostic @5 19
C03 14  X  ENG  @0 Prognosis @5 19
C03 14  X  SPA  @0 Pronóstico @5 19
C03 15  X  FRE  @0 Adulte @5 20
C03 15  X  ENG  @0 Adult @5 20
C03 15  X  SPA  @0 Adulto @5 20
C07 01  X  FRE  @0 Homme
C07 01  X  ENG  @0 Human
C07 01  X  SPA  @0 Hombre
C07 02  X  FRE  @0 Système nerveux pathologie @5 37
C07 02  X  ENG  @0 Nervous system diseases @5 37
C07 02  X  SPA  @0 Sistema nervioso patología @5 37
C07 03  X  FRE  @0 Système nerveux central pathologie @5 38
C07 03  X  ENG  @0 Central nervous system disease @5 38
C07 03  X  SPA  @0 Sistema nervosio central patología @5 38
C07 04  X  FRE  @0 Encéphale pathologie @5 39
C07 04  X  ENG  @0 Cerebral disorder @5 39
C07 04  X  SPA  @0 Encéfalo patología @5 39
C07 05  X  FRE  @0 Extrapyramidal syndrome @5 40
C07 05  X  ENG  @0 Extrapyramidal syndrome @5 40
C07 05  X  SPA  @0 Extrapiramidal síndrome @5 40
C07 06  X  FRE  @0 Maladie dégénérative @5 41
C07 06  X  ENG  @0 Degenerative disease @5 41
C07 06  X  SPA  @0 Enfermedad degenerativa @5 41
N21       @1 266
N82       @1 PSI

Format Inist (serveur)

NO : PASCAL 02-0456874 INIST
ET : Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis
AU : MERELLO (Marcelo); NOUZEILLES (Maria I.); PIRAN ARCE (Gabriel); LEIGUARDA (Ramon)
AF : Movement Disorders Section, Raul Carrea Institute for Neurological Research (FLENI)/Buenos Aires/Argentine (1 aut., 2 aut., 3 aut.); Department of Neurology, Raul Carrea Institute for Neurological Research (FLENI)/Buenos Aires/Argentine (1 aut., 4 aut.)
DT : Publication en série; Courte communication, note brève; Niveau analytique
SO : Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. 4; Pp. 795-798; Bibl. 23 ref.
LA : Anglais
EA : Clinical idiopathic Parkinson's disease (PD) diagnosis requires following strict clinical criteria. Final definitive diagnosis can only be made after pathological confirmation and, despite following clinical criteria, several cases are mis-diagnosed. We assessed sensitivity and specificity of acute challenge with levodopa (L-dopa) to predict sustained long-term L-dopa responsiveness as a major criterion for clinical diagnosis of PD. A consecutive series of 82 patients first seen at a movement disorders clinic with a parkinsonian syndrome without specific diagnosis was included. A second examiner, blind to the presumptive diagnosis, performed in each patient an acute challenge with 250/50 mg of L-dopa-carbidopa and rated the test as positive or negative according to whether values reached a minimal 30% of improvement on UPDRS scores. Positive tests were considered supportive of presumptive clinical diagnosis of Parkinson's disease. Blind to test results and according to clinical presumption, the first examiner started patient treatment with the necessary L-dopa dose or, alternatively, until reaching 1 g for 1 month in those who failed to display a positive test response. At 24 month follow-up, they were re-tested with 1 g for 1 month when required. At this point, clinical criteria of the U.K. Parkinson's Disease Society Brain Bank were applied and definitive clinical diagnosis of PD was made. Sensitivity, specificity, and positive predictive ratio for acute challenge were calculated. Overall sensitivity and specificity of acute L-dopa challenge to predict clinical diagnosis of PD was 70.9% and 81.4%, respectively; positive predictive ratio was 88.6%. When patients were divided into three groups according to their UPDRS motor section score at initial examination, sensitivity and specificity varied: Group I (≤ 10), 71.4% and 100%; Group II (11-20), 75% and 75%; and Group III (≥21), 36.4% and 87%, respectively. Positive predictive ratio increased to 100% in Group I and to 87.5% in Group III. The positive result of initial acute L-dopa challenge predicts chronic L-dopa responsiveness as major criterion of PD in all patients with UPDRS motor scores lower than 10.
CC : 002B17G; 235
FD : Parkinson maladie; Idiopathique; Epreuve pharmacologique; Lévodopa; Antiparkinsonien; Long terme; Chimiothérapie; Sensibilité; Spécificité; Valeur prédictive; Evolution; Diagnostic; Traitement; Pronostic; Adulte
FG : Homme; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative
ED : Parkinson disease; Idiopathic; Pharmacologic test; Levodopa; Antiparkinson agent; Long term; Chemotherapy; Sensitivity; Specificity; Predictive value; Evolution; Diagnosis; Treatment; Prognosis; Adult
EG : Human; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease
SD : Parkinson enfermedad; Idiopático; Prueba farmacológica; Levodopa; Antiparkinsoniano; Largo plazo; Quimioterapia; Sensibilidad; Especificidad; Valor predictivo; Evolución; Diagnóstico; Tratamiento; Pronóstico; Adulto
LO : INIST-20953.354000108922560290
ID : 02-0456874

Links to Exploration step

Pascal:02-0456874

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis</title>
<author>
<name sortKey="Merello, Marcelo" sort="Merello, Marcelo" uniqKey="Merello M" first="Marcelo" last="Merello">Marcelo Merello</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Movement Disorders Section, Raul Carrea Institute for Neurological Research (FLENI)</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation>
<inist:fA14 i1="02">
<s1>Department of Neurology, Raul Carrea Institute for Neurological Research (FLENI)</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Nouzeilles, Maria I" sort="Nouzeilles, Maria I" uniqKey="Nouzeilles M" first="Maria I." last="Nouzeilles">Maria I. Nouzeilles</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Movement Disorders Section, Raul Carrea Institute for Neurological Research (FLENI)</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Piran Arce, Gabriel" sort="Piran Arce, Gabriel" uniqKey="Piran Arce G" first="Gabriel" last="Piran Arce">Gabriel Piran Arce</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Movement Disorders Section, Raul Carrea Institute for Neurological Research (FLENI)</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Leiguarda, Ramon" sort="Leiguarda, Ramon" uniqKey="Leiguarda R" first="Ramon" last="Leiguarda">Ramon Leiguarda</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Department of Neurology, Raul Carrea Institute for Neurological Research (FLENI)</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">02-0456874</idno>
<date when="2002">2002</date>
<idno type="stanalyst">PASCAL 02-0456874 INIST</idno>
<idno type="RBID">Pascal:02-0456874</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002683</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis</title>
<author>
<name sortKey="Merello, Marcelo" sort="Merello, Marcelo" uniqKey="Merello M" first="Marcelo" last="Merello">Marcelo Merello</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Movement Disorders Section, Raul Carrea Institute for Neurological Research (FLENI)</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation>
<inist:fA14 i1="02">
<s1>Department of Neurology, Raul Carrea Institute for Neurological Research (FLENI)</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Nouzeilles, Maria I" sort="Nouzeilles, Maria I" uniqKey="Nouzeilles M" first="Maria I." last="Nouzeilles">Maria I. Nouzeilles</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Movement Disorders Section, Raul Carrea Institute for Neurological Research (FLENI)</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Piran Arce, Gabriel" sort="Piran Arce, Gabriel" uniqKey="Piran Arce G" first="Gabriel" last="Piran Arce">Gabriel Piran Arce</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Movement Disorders Section, Raul Carrea Institute for Neurological Research (FLENI)</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Leiguarda, Ramon" sort="Leiguarda, Ramon" uniqKey="Leiguarda R" first="Ramon" last="Leiguarda">Ramon Leiguarda</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Department of Neurology, Raul Carrea Institute for Neurological Research (FLENI)</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint>
<date when="2002">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adult</term>
<term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Diagnosis</term>
<term>Evolution</term>
<term>Idiopathic</term>
<term>Levodopa</term>
<term>Long term</term>
<term>Parkinson disease</term>
<term>Pharmacologic test</term>
<term>Predictive value</term>
<term>Prognosis</term>
<term>Sensitivity</term>
<term>Specificity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Parkinson maladie</term>
<term>Idiopathique</term>
<term>Epreuve pharmacologique</term>
<term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Long terme</term>
<term>Chimiothérapie</term>
<term>Sensibilité</term>
<term>Spécificité</term>
<term>Valeur prédictive</term>
<term>Evolution</term>
<term>Diagnostic</term>
<term>Traitement</term>
<term>Pronostic</term>
<term>Adulte</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Clinical idiopathic Parkinson's disease (PD) diagnosis requires following strict clinical criteria. Final definitive diagnosis can only be made after pathological confirmation and, despite following clinical criteria, several cases are mis-diagnosed. We assessed sensitivity and specificity of acute challenge with levodopa (L-dopa) to predict sustained long-term L-dopa responsiveness as a major criterion for clinical diagnosis of PD. A consecutive series of 82 patients first seen at a movement disorders clinic with a parkinsonian syndrome without specific diagnosis was included. A second examiner, blind to the presumptive diagnosis, performed in each patient an acute challenge with 250/50 mg of L-dopa-carbidopa and rated the test as positive or negative according to whether values reached a minimal 30% of improvement on UPDRS scores. Positive tests were considered supportive of presumptive clinical diagnosis of Parkinson's disease. Blind to test results and according to clinical presumption, the first examiner started patient treatment with the necessary L-dopa dose or, alternatively, until reaching 1 g for 1 month in those who failed to display a positive test response. At 24 month follow-up, they were re-tested with 1 g for 1 month when required. At this point, clinical criteria of the U.K. Parkinson's Disease Society Brain Bank were applied and definitive clinical diagnosis of PD was made. Sensitivity, specificity, and positive predictive ratio for acute challenge were calculated. Overall sensitivity and specificity of acute L-dopa challenge to predict clinical diagnosis of PD was 70.9% and 81.4%, respectively; positive predictive ratio was 88.6%. When patients were divided into three groups according to their UPDRS motor section score at initial examination, sensitivity and specificity varied: Group I (≤ 10), 71.4% and 100%; Group II (11-20), 75% and 75%; and Group III (≥21), 36.4% and 87%, respectively. Positive predictive ratio increased to 100% in Group I and to 87.5% in Group III. The positive result of initial acute L-dopa challenge predicts chronic L-dopa responsiveness as major criterion of PD in all patients with UPDRS motor scores lower than 10.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0885-3185</s0>
</fA01>
<fA03 i2="1">
<s0>Mov. disord.</s0>
</fA03>
<fA05>
<s2>17</s2>
</fA05>
<fA06>
<s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>MERELLO (Marcelo)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>NOUZEILLES (Maria I.)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>PIRAN ARCE (Gabriel)</s1>
</fA11>
<fA11 i1="04" i2="1">
<s1>LEIGUARDA (Ramon)</s1>
</fA11>
<fA14 i1="01">
<s1>Movement Disorders Section, Raul Carrea Institute for Neurological Research (FLENI)</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>Department of Neurology, Raul Carrea Institute for Neurological Research (FLENI)</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA20>
<s1>795-798</s1>
</fA20>
<fA21>
<s1>2002</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>20953</s2>
<s5>354000108922560290</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2002 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>23 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>02-0456874</s0>
</fA47>
<fA60>
<s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Movement disorders</s0>
</fA64>
<fA66 i1="01">
<s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>Clinical idiopathic Parkinson's disease (PD) diagnosis requires following strict clinical criteria. Final definitive diagnosis can only be made after pathological confirmation and, despite following clinical criteria, several cases are mis-diagnosed. We assessed sensitivity and specificity of acute challenge with levodopa (L-dopa) to predict sustained long-term L-dopa responsiveness as a major criterion for clinical diagnosis of PD. A consecutive series of 82 patients first seen at a movement disorders clinic with a parkinsonian syndrome without specific diagnosis was included. A second examiner, blind to the presumptive diagnosis, performed in each patient an acute challenge with 250/50 mg of L-dopa-carbidopa and rated the test as positive or negative according to whether values reached a minimal 30% of improvement on UPDRS scores. Positive tests were considered supportive of presumptive clinical diagnosis of Parkinson's disease. Blind to test results and according to clinical presumption, the first examiner started patient treatment with the necessary L-dopa dose or, alternatively, until reaching 1 g for 1 month in those who failed to display a positive test response. At 24 month follow-up, they were re-tested with 1 g for 1 month when required. At this point, clinical criteria of the U.K. Parkinson's Disease Society Brain Bank were applied and definitive clinical diagnosis of PD was made. Sensitivity, specificity, and positive predictive ratio for acute challenge were calculated. Overall sensitivity and specificity of acute L-dopa challenge to predict clinical diagnosis of PD was 70.9% and 81.4%, respectively; positive predictive ratio was 88.6%. When patients were divided into three groups according to their UPDRS motor section score at initial examination, sensitivity and specificity varied: Group I (≤ 10), 71.4% and 100%; Group II (11-20), 75% and 75%; and Group III (≥21), 36.4% and 87%, respectively. Positive predictive ratio increased to 100% in Group I and to 87.5% in Group III. The positive result of initial acute L-dopa challenge predicts chronic L-dopa responsiveness as major criterion of PD in all patients with UPDRS motor scores lower than 10.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002B17G</s0>
</fC02>
<fC02 i1="02" i2="X">
<s0>235</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Idiopathique</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Idiopathic</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Idiopático</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Epreuve pharmacologique</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Pharmacologic test</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Prueba farmacológica</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Antiparkinsonien</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Antiparkinson agent</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Antiparkinsoniano</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Long terme</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Long term</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Largo plazo</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Chimiothérapie</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>Chemotherapy</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Quimioterapia</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE">
<s0>Sensibilité</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG">
<s0>Sensitivity</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA">
<s0>Sensibilidad</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE">
<s0>Spécificité</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG">
<s0>Specificity</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA">
<s0>Especificidad</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE">
<s0>Valeur prédictive</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG">
<s0>Predictive value</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA">
<s0>Valor predictivo</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE">
<s0>Evolution</s0>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG">
<s0>Evolution</s0>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA">
<s0>Evolución</s0>
<s5>16</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE">
<s0>Diagnostic</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG">
<s0>Diagnosis</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA">
<s0>Diagnóstico</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE">
<s0>Traitement</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG">
<s0>Treatment</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA">
<s0>Tratamiento</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE">
<s0>Pronostic</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG">
<s0>Prognosis</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA">
<s0>Pronóstico</s0>
<s5>19</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE">
<s0>Adulte</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG">
<s0>Adult</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA">
<s0>Adulto</s0>
<s5>20</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Homme</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Human</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Hombre</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE">
<s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG">
<s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA">
<s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE">
<s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG">
<s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA">
<s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fN21>
<s1>266</s1>
</fN21>
<fN82>
<s1>PSI</s1>
</fN82>
</pA>
</standard>
<server>
<NO>PASCAL 02-0456874 INIST</NO>
<ET>Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis</ET>
<AU>MERELLO (Marcelo); NOUZEILLES (Maria I.); PIRAN ARCE (Gabriel); LEIGUARDA (Ramon)</AU>
<AF>Movement Disorders Section, Raul Carrea Institute for Neurological Research (FLENI)/Buenos Aires/Argentine (1 aut., 2 aut., 3 aut.); Department of Neurology, Raul Carrea Institute for Neurological Research (FLENI)/Buenos Aires/Argentine (1 aut., 4 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. 4; Pp. 795-798; Bibl. 23 ref.</SO>
<LA>Anglais</LA>
<EA>Clinical idiopathic Parkinson's disease (PD) diagnosis requires following strict clinical criteria. Final definitive diagnosis can only be made after pathological confirmation and, despite following clinical criteria, several cases are mis-diagnosed. We assessed sensitivity and specificity of acute challenge with levodopa (L-dopa) to predict sustained long-term L-dopa responsiveness as a major criterion for clinical diagnosis of PD. A consecutive series of 82 patients first seen at a movement disorders clinic with a parkinsonian syndrome without specific diagnosis was included. A second examiner, blind to the presumptive diagnosis, performed in each patient an acute challenge with 250/50 mg of L-dopa-carbidopa and rated the test as positive or negative according to whether values reached a minimal 30% of improvement on UPDRS scores. Positive tests were considered supportive of presumptive clinical diagnosis of Parkinson's disease. Blind to test results and according to clinical presumption, the first examiner started patient treatment with the necessary L-dopa dose or, alternatively, until reaching 1 g for 1 month in those who failed to display a positive test response. At 24 month follow-up, they were re-tested with 1 g for 1 month when required. At this point, clinical criteria of the U.K. Parkinson's Disease Society Brain Bank were applied and definitive clinical diagnosis of PD was made. Sensitivity, specificity, and positive predictive ratio for acute challenge were calculated. Overall sensitivity and specificity of acute L-dopa challenge to predict clinical diagnosis of PD was 70.9% and 81.4%, respectively; positive predictive ratio was 88.6%. When patients were divided into three groups according to their UPDRS motor section score at initial examination, sensitivity and specificity varied: Group I (≤ 10), 71.4% and 100%; Group II (11-20), 75% and 75%; and Group III (≥21), 36.4% and 87%, respectively. Positive predictive ratio increased to 100% in Group I and to 87.5% in Group III. The positive result of initial acute L-dopa challenge predicts chronic L-dopa responsiveness as major criterion of PD in all patients with UPDRS motor scores lower than 10.</EA>
<CC>002B17G; 235</CC>
<FD>Parkinson maladie; Idiopathique; Epreuve pharmacologique; Lévodopa; Antiparkinsonien; Long terme; Chimiothérapie; Sensibilité; Spécificité; Valeur prédictive; Evolution; Diagnostic; Traitement; Pronostic; Adulte</FD>
<FG>Homme; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative</FG>
<ED>Parkinson disease; Idiopathic; Pharmacologic test; Levodopa; Antiparkinson agent; Long term; Chemotherapy; Sensitivity; Specificity; Predictive value; Evolution; Diagnosis; Treatment; Prognosis; Adult</ED>
<EG>Human; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease</EG>
<SD>Parkinson enfermedad; Idiopático; Prueba farmacológica; Levodopa; Antiparkinsoniano; Largo plazo; Quimioterapia; Sensibilidad; Especificidad; Valor predictivo; Evolución; Diagnóstico; Tratamiento; Pronóstico; Adulto</SD>
<LO>INIST-20953.354000108922560290</LO>
<ID>02-0456874</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002683 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002683 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:02-0456874
   |texte=   Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024